The development and antimicrobial properties of peptaibiotics and peptaibols are discussed. Also, the role of emerging peptaibol analogues, of alamethicin, e.g., harzianins HC, trichotoxin, and antiamoebin, is outlined.
No takes yet. Share an insight, caveat, or question.
Hervé Duclohier (2007) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: